Ginsenoside Rk2 (GRk2) significantly reduces serum AST/ALT levels, attenuates hepatic steatosis, and reduces lipid droplet accumulation in chronic-binge ethanol-fed mice by a mechanism related to the modulation of SREBP-1/AMP-activated protein kinase (AMPK) signaling through downregulation of fatty acid synthase (FASN), stearoyl-CoA desaturase1 (SCD1), and SREBP-1 expression, and upregulation of phosphorylated AMPK, which inhibit hepatic steatosis. The gene discussed is FASN; the disease is fatty liver disease.